Table 3.
Biologics able to inhibit NLRP3 inflammasome in digestive diseases.
| Drugs | NLRP3 signaling molecular target | Experimental model | Reference | Clinical trials |
|---|---|---|---|---|
| Liraglutide | Inhibition of NLRP3 inflammasome and pyroptosis activation | NAFLD | (185–187) |
NCT02147925 NCT03068065 NCT01399645 etc |
| Lactobacillus casei atc 393 | Inhibition of NLRP3/Caspase-1/IL-1βpathway Reduction of NLRP3, caspase-1, IL-1β and IL-18 |
UC | (188) | null |
| β-acetylaminohexosidase (Amuc_2109) | Inhibition of TNF-α, IL-1β, IL-6 and NLRP3 expression | Colitis | (189) | null |
| AC-YVAD-CMK | Inhibition of caspase-1 Regulating the NF-κB pathway and P38 MAPK pathway |
Acute gastric injury | (190) | null |
| Anakinra | IL-1RI inhibitor | Acute liver injury | (191) | null |
| Kinsenoside | Inhibition of NF-κB/NLRP3 signaling pathway | NASH | (192) | null |